Oncotarget

Research Perspectives:

MEK inhibitors in non-V600 BRAF mutations and fusions

Douglas B. Johnson _, Caroline A. Nebhan and Marcus S. Noel

PDF  |  Full Text  |  How to cite  |  Order a Reprint

Oncotarget. 2020; 11:3900-3903. https://doi.org/10.18632/oncotarget.27788

Metrics: PDF 859 views  |   Full Text 1174 views  |   ?  


Abstract

Douglas B. Johnson1, Caroline A. Nebhan1 and Marcus S. Noel2

1 Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA

2 Department of Medicine, Georgetown University Medical Center, Washington, DC, USA

Correspondence to:

Douglas B. Johnson,email: douglas.b.johnson@vumc.org

Keywords: trametinib; MEK; BRAF; atypical; fusion

Received: October 09, 2020     Accepted: October 13, 2020     Published: November 03, 2020

Copyright: © 2020 Johnson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Mutations in BRAF at the 600th codon have proven sensitive to combination BRAF and MEK inhibition. Mutations outside this codon, however, are approximately as common but do not have approved targeted therapy approaches. Herein, we discuss targeting these non-V600 mutation and fusions in BRAF with MEK inhibitors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27788